Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

IMvigor011: adjuvant atezolizumab versus placebo for ctDNA-positive MIBC after cystectomy

Phase 3 randomized trial of adjuvant atezolizumab versus placebo in patients with muscle-invasive bladder cancer who are ctDNA-positive after cystectomy. ClinicalTrials.gov lists the study as completed (status verified October 2026; last update posted November 6, 2026; actual completion date October 1, 2026; n=761).

Hoffmann-La Roche